Eli Lilly's Pipeline Shows Early Promising Results in JAK2 Inhibitor Study

Eli Lilly (LLY) announced new data from its Phase 1 AJX-101 study, showing an investigational type II JAK2 inhibitor with a favorable safety profile and clinical activity for myelofibrosis patients resistant to current treatments. Jefferies also raised LLY's price target following positive results in obesity-related trials.

By Rameen Kasana Thu, June 18, 2026 at 11:08 AM GMT+3 2 min read · Yahoo Finance · June 18, 2026, 08:08 UTC

Tickers: $LLY

Topics: Eli Lilly JAK2 inhibitor myelofibrosis treatment pipeline progress

Read the full article at Yahoo Finance

More World news

Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC
Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC